Romidepsin in T-Cell Malignancies Allo-SCT

Phase 1, open-label, single-arm trial of romidepsin in cutaneous T-cell lymphoma (CTCL), T-cell prolymphocytic leukemia (T-PLL), T-cell large granular lymphocytic leukemia and 2 more, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Toxicity of Romidepsin with Busulfan and Fludarabine Conditioning Therapy at 30 days and Efficacy of Romidepsin with Busulfan and Fludarabine Conditioning Therapy. Started Dec 2017; status: completed.